Exploratory analysis of retreatment with brentuximab vedotin (BV) after frontline treatment with brentuximab vedotin and CHP (A plus CHP) for patients (pts) with CD30+peripheral T-cell lymphoma (ECHELON-2)
Authors
Trumper, L.Pro, B.
Horwitz, S.
O'Connor, O.
Tilly, H.
Choi, I.
Gritti, G.
Fox, C.
Alpdogan, O.
Mayer, J.
Briones, J.
Jacobsen, E.
Pezzutto, A.
Demeter, J.
Gurion, R.
Jurczak, W.
Kuo, C. Y.
Opat, S.
Little, M.
Brown, L.
Puhlmann, M.
Illidge, Timothy M
Affiliation
Univ Med Gottingen, Gottingen, GermanyIssue Date
2020